» Articles » PMID: 8276210

Saccharomyces Boulardii Inhibits Secretagogue-mediated Adenosine 3',5'-cyclic Monophosphate Induction in Intestinal Cells

Overview
Specialty Gastroenterology
Date 1994 Jan 1
PMID 8276210
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: The yeast Saccharomyces boulardii inhibits the secretion induced by cholera toxin (CT) in rat jejunum. The present study was aimed at unraveling the mechanism by which S. boulardii protects intestinal cells against CT.

Methods: CT-induced adenosine 3',5'-cyclic monophosphate (cAMP) levels were measured by radioimmunoassay in intestinal epithelial cells IEC-6 or HT29-D4 cells exposed to whole yeast or to culture medium conditioned by S. boulardii (Sb-conditioned medium).

Results: Sb-conditioned medium significantly reduced CT-induced cAMP levels in IEC-6 cells. This effect was eliminated by heat treatment, trypsin hydrolysis, and trichloroacetic acid precipitation of Sb-conditioned medium. When conditioned medium was fractionated on polyacrylamide gel under nondenaturing conditions, neutralizing activity was shown to be associated with a 120-kilodalton protein. The neutralizing activity was not attributable to proteolytic activity against CT. Sb-conditioned medium reduced the amount of cAMP induced by CT as well as Escherichia coli thermolabile toxin or forskolin in HT29-D4 cells. The modulation of secretagogue-induced cAMP by Sb-conditioned medium did not occur in the presence of pertussis toxin.

Conclusions: These results suggest that the neutralization of CT by S. boulardii is mediated by a specific yeast protein and involves a receptor that is negatively coupled to adenylate cyclase.

Citing Articles

Alleviates Colitis by Regulating FXR-NLRP3 Mediated Macrophage Pyroptosis.

Yang L, Li W, Zhao Q, Mo Q, Liu T, Cao H J Inflamm Res. 2025; 18:3161-3176.

PMID: 40065908 PMC: 11891491. DOI: 10.2147/JIR.S504957.


Enhancing probiotic impact: engineering for optimal acetic acid production and gastric passage tolerance.

Trindade de Carvalho B, Subotic A, Vandecruys P, Deleu S, Vermeire S, Thevelein J Appl Environ Microbiol. 2024; 90(6):e0032524.

PMID: 38752748 PMC: 11218656. DOI: 10.1128/aem.00325-24.


Investigating the Efficacy of in Metabolic Syndrome Treatment: A Narrative Review of What Is Known So Far.

Egea M, de Oliveira Filho J, Lemes A Int J Mol Sci. 2023; 24(15).

PMID: 37569390 PMC: 10418856. DOI: 10.3390/ijms241512015.


: What Makes It Tick as Successful Probiotic?.

Pais P, Almeida V, Yilmaz M, Teixeira M J Fungi (Basel). 2020; 6(2).

PMID: 32512834 PMC: 7344949. DOI: 10.3390/jof6020078.


Diversity of CNCM I-745 mechanisms of action against intestinal infections.

Czerucka D, Rampal P World J Gastroenterol. 2019; 25(18):2188-2203.

PMID: 31143070 PMC: 6526157. DOI: 10.3748/wjg.v25.i18.2188.